SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 3.51 |
| Enterprise Value ($M) | 3.40 |
| Book Value ($M) | 0.38 |
| Book Value / Share | 0.16 |
| Price / Book | 9.18 |
| NCAV ($M) | -11.64 |
| NCAV / Share | -4.91 |
| Price / NCAV | -0.30 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -43.34 |
| Return on Assets (ROA) | -0.81 |
| Return on Equity (ROE) | -1.10 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.48 |
| Current Ratio | 2.48 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 14.36 |
| Assets | 26.38 |
| Liabilities | 26.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 6,329 | 18,163 | 34.85 | |
| 10,438 | 33,368 | 31.28 | |
| 6,494 | 18,174 | 35.73 | |
| 2,358 | 10,736 | 21.96 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| THTX – Theratechnologies Inc. | TIL – Instil Bio, Inc. |
| TLSA – Tiziana Life Sciences Ltd | TNXP – Tonix Pharmaceuticals Holding Corp. |
| TPST – Tempest Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io